Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.
Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction of abortion Sixty patients with undisturbed ectopic pregnancy were classified into three equal groups. Group I: The control group that contained women who were undergoing laparoscopic salpingectomy, Group II: Patients who received letrozole (5 mg d-1) for 10 d, and Group III: Patients who received letrozole (10 mg d-1) for 10 d. After that, the human chorionic gonadotropin (β-hCG) levels were determined for the first day and after 11 d of treating. letrozole (10 mg d-1) markedly reduced the receptors of estrogen and progesterone, and subsequent vascular endothelial growth factor signals, resulting in marked apoptosis in the placenta tissue. The utilization of letrozole at a dose of 10 mg d-1 for inducement of abortion typically results in a substantial high-successful rate without any severe side effects.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group I (GI) | Active Comparator | Patients who were undergoing surgical treatment |
|
| low dose letrozole group II (GII) | Experimental | patients who were medically treated with 5 mg of letrozole |
|
| High dose letrozole group (GIII) | Experimental | patients who were medically treated with 10 mg of letrozole using |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Letrozole tablets | Drug | GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III) |
| Measure | Description | Time Frame |
|---|---|---|
| β-hCG level | A quantitative human chorionic gonadotropin | The β-hCG levels were assessed on the 1st of treatment |
| β-hCG level | A quantitative human chorionic gonadotropin | The β-hCG levels were assessed on the 11th day of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Complete blood count (CBC) | Complete blood count | Assessed on the 1st day of treatment |
| Alanine Amino Transferase (ALT) | Liver enzyme |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ahmed I Heraiz, MD | Zagazig University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mohamed ALI Alabiad | Zagazig | Sharqia Province | 14150 | Egypt |
Not provided
Not provided
| ID | Type | URL | Comment |
|---|---|---|---|
| Study Protocol | View IPD |
Table Statistical analysis Master sheet raw data (excel sheet)
the data will become available after one month from the approval and will be available for three months
you can send a Data request email to Dr: Mohamed at drno99@yahoo.com
Not provided
Not provided
| ID | Term |
|---|---|
| D011271 | Pregnancy, Ectopic |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077289 | Letrozole |
| ID | Term |
|---|---|
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| laparoscopic salpingectomy | Procedure | laparoscopic salpingectomy |
|
| Assessed on the 1st and 11th day of treatment |
| Aspartate aminotransferase (AST) | Liver enzyme | Assessed on the 1st and 11th day of treatment |
| Serum creatinine | Renal function test | Assessed on the 1st and 11th day of treatment |
| Blood urea | Renal function test | Assessed on the 1st and 11th day of treatment |
| Complete blood count (CBC) | Complete blood count | Assessed on the 11th day of treatment |
| Alanine Amino Transferase (ALT) | Liver enzyme | Assessed on the 11th day of treatment |
| Aspartate aminotransferase (AST) | Liver enzyme | Assessed on the 11th day of treatment |
| Serum creatinine | Renal function test | Assessed on the 11th day of treatment |
| Blood urea | Renal function test | Assessed on the 11th day of treatment |
you can send a Data request e-mail to Dr Mohamed at drno99@yahoo.com |
| drno99@yahoo.com | Statistical Analysis Plan | View IPD | you can send a Data request e-mail to Dr Mohamed at drno99@yahoo.com |
| Informed Consent Form | View IPD | you can send a Data request e-mail to Dr Mohamed at drno99@yahoo.com |
| Individual Participant Data Set | View IPD | you can send a Data request e-mail to Dr Mohamed at drno99@yahoo.com |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |